Physician Assistant · Houston, TX
NPI
1396162814
Since 2014
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
9214 Angelas Meadow Ln
Houston, TX, 77095
Phone (254) 644-5101
Groups this clinician bills Medicare through
Medicare paid, 2024
$91K
1,864 services
Medicare patients, 2024
312
Average age 73
Drug cost, 2024
$292K
1,633 prescriptions
Company payments, 2025
$236
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Basil Kaaki was code 99213 (office e&m - established), 290 times for 216 patients. In total Basil Kaaki billed 1,864 services in 35 codes, and Medicare paid $91K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 290 | 216 | $52.86 | $15K |
| 84403 Clinical Chemistry | Office | 262 | 171 | $25.12 | $6,582 |
| 84270 Clinical Chemistry | Office | 258 | 169 | $21.16 | $5,459 |
| 82670 Clinical Chemistry | Office | 229 | 146 | $27.17 | $6,223 |
| 84153 Clinical Chemistry | Office | 228 | 143 | $17.63 | $4,020 |
| 99214 Office E&M - Established | Office | 117 | 94 | $80.81 | $9,455 |
| 51798 Ultrasound - Nonspecific | Office | 98 | 86 | $7.89 | $773 |
| 84154 Clinical Chemistry | Office | 64 | 46 | $17.46 | $1,117 |
| 86316 Immunoassay | Office | 62 | 44 | $19.84 | $1,230 |
| 11980 Skin | Office | 49 | 28 | $61.53 | $3,015 |
| 99212 Office E&M - Established | Office | 46 | 40 | $31.79 | $1,462 |
| J3490 Unclassified drugs | Office | 39 | 23 | $881.02 | $34K |
| G0103 Prostate cancer screening; prostate specific antigen test (psa) | Office | 14 | 14 | $18.92 | $265 |
By year: 2022 $80K for 2,030 services; 2023 $83K for 2,071 services; 2024 $91K for 1,864 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 84403 Clinical Chemistry | 262 | 171 | $25.12 | $6,582 |
| 84270 Clinical Chemistry | 258 | 169 | $21.16 | $5,459 |
| 82670 Clinical Chemistry | 229 | 146 | $27.17 | $6,223 |
| 84153 Clinical Chemistry | 228 | 143 | $17.63 | $4,020 |
| 84154 Clinical Chemistry | 64 | 46 | $17.46 | $1,117 |
| 86316 Immunoassay | 62 | 44 | $19.84 | $1,230 |
| G0103 Prostate cancer screening; prostate specific antigen test (psa) | 14 | 14 | $18.92 | $265 |
Medicare prescription drug claims, 2024
In 2024, the drug Basil Kaaki prescribed most often to Medicare patients was Tamsulosin Hcl, with 305 prescriptions and refills. In total Basil Kaaki wrote 1,633 Medicare prescriptions that cost $292K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 305 | 875 | 110 | $5,531 |
| Testosterone Cypionate Generic | 167 | 282 | 52 | $7,125 |
| Anastrozole Generic | 141 | 376 | 45 | $537 |
| Xyosted Testosterone Enanthate | 99 | 112 | 15 | $69K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 89 | 263 | 30 | $2,113 |
| Testosterone Enanthate Generic | 85 | 151 | 32 | $7,147 |
| Gemtesa Vibegron | 80 | 177 | 24 | $83K |
| Testosterone Generic | 79 | 135 | 27 | $16K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 68 | 177 | 21 | $1,394 |
| Cabergoline Generic | 59 | 122 | 18 | $7,245 |
| Finasteride Generic | 52 | 156 | 21 | $578 |
| Myrbetriq Mirabegron | 50 | 88 | 14 | $40K |
| Solifenacin Succinate Generic | 40 | 112 | 16 | $3,262 |
| Silodosin Generic | 32 | 89 | 13 | $4,247 |
| Tadalafil Generic | 25 | 41 | Under 11 | $859 |
Brand drugs: - claims; generic drugs: 1,323 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Basil Kaaki $236 ($236 in general payments such as food, travel and fees) from 3 companies. The largest payer was Tolmar, Inc. with $184.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.